microRNA-3646 serves as a diagnostic marker and mediates the inflammatory response induced by acute coronary syndrome

References

• Anchah L, Hassali MA, Lim MS, et al. Health related quality of life assessment in acute coronary syndrome patients: the effectiveness of early phase I cardiac rehabilitation. Health Qual Life Outcomes. 2017;15(1):10.
   PubMed Web of Science ®Google Scholar
• Carreras ET, Mega JL. Role of oral anticoagulants in patients after an acute coronary syndrome. Arterioscler Thromb Vasc Biol. 2015;35(3):520–524.
   PubMed Web of Science ®Google Scholar
• Nikus K, Birnbaum Y, Eskola M, et al. Updated electrocardiographic classification of acute coronary syndromes. Curr Cardiol Rev. 2014;10(3):229–236.
   PubMedGoogle Scholar
• Widimsky P, Rohac F, Stasek J, et al. Primary angioplasty in acute myocardial infarction with right bundle branch block: should new onset right bundle branch block be added to future guidelines as an indication for reperfusion therapy? Eur Heart J. 2012;33(1):86–95.
   PubMed Web of Science ®Google Scholar
• Boon RA. MicroRNAs control vascular endothelial growth factor signaling. Circ Res. 2012;111(11):1388–1390.
   PubMed Web of Science ®Google Scholar
• Navickas R, Gal D, Laucevicius A, et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res. 2016;111(4):322–337.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222.
   PubMed Web of Science ®Google Scholar
• Bai R, Yang Q, Xi R, et al. miR-941 as a promising biomarker for acute coronary syndrome. BMC Cardiovasc Disord. 2017;17(1):227.
   PubMedGoogle Scholar
• Wang M, Ji Y, Cai S, et al. MiR-206 suppresses the progression of coronary artery disease by modulating vascular endothelial growth factor (VEGF) expression. Med Sci Monit. 2016;22:5011–5020.
   PubMed Web of Science ®Google Scholar
• Ling H, Guo Z, Du S, et al. Serum exosomal miR-122-5p is a new biomarker for both acute coronary syndrome and underlying coronary artery stenosis. Biomarkers. 2020;25(7):539–547.
   PubMed Web of Science ®Google Scholar
• Sun D, Ma T, Zhang Y, et al. Overexpressed miR-335-5p reduces atherosclerotic vulnerable plaque formation in acute coronary syndrome. J Clin Lab Anal. 2021;35(2):e23608.
   PubMed Web of Science ®Google Scholar
• Barraclough JY, Joglekar MV, Januszewski AS, et al. A MicroRNA signature in acute coronary syndrome patients and modulation by colchicine. J Cardiovasc Pharmacol Ther. 2020;25(5):444–455.
   PubMed Web of Science ®Google Scholar
• Fan JL, Zhang L, Bo XH. MiR-126 on mice with coronary artery disease by targeting S1PR2. Eur Rev Med Pharmacol Sci. 2020;24(2):893–904.
   PubMed Web of Science ®Google Scholar
• Kang X, Cao S, Ji Z, et al. miR-3646 promotes vascular inflammation and augments vascular smooth muscle cell proliferation and migration in progression of coronary artery disease by directly targeting RHOH. Int J Clin Exp Pathol. 2018;11(12):5830–5839.
   PubMed Web of Science ®Google Scholar
• Liu W, Miao Y, Zhang L, et al. MiR-211 protects cerebral ischemia/reperfusion injury by inhibiting cell apoptosis. Bioengineered. 2020;11(1):189–200.
   PubMed Web of Science ®Google Scholar
• Xu HM, Sui FH, Sun MH, et al. Downregulated microRNA-224 aggravates vulnerable atherosclerotic plaques and vascular remodeling in acute coronary syndrome through activation of the TGF-beta/Smad pathway. J Cell Physiol. 2019;234(3):2537–2551.
   PubMed Web of Science ®Google Scholar
• Lequin RM. Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA). Clin Chem. 2005;51(12):2415–2418.
   PubMed Web of Science ®Google Scholar
• Kumar D, Narang R, Sreenivas V, et al. Circulatory miR-133b and miR-21 as novel biomarkers in early prediction and diagnosis of coronary artery disease. Genes (Basel). 2020;11:2.
   Web of Science ®Google Scholar
• Navickas R, Gal D, Laucevičius A, et al. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. Cardiovasc Res. 2016;111(4):322–337.
   PubMed Web of Science ®Google Scholar
• Wang C, Jing Q. Non-coding RNAs as biomarkers for acute myocardial infarction. Acta Pharmacol Sin. 2018;39(7):1110–1119.
   PubMed Web of Science ®Google Scholar
• Yang TT, Liu CG, Gao SC, et al. The serum exosome derived MicroRNA-135a, −193b, and −384 were potential alzheimer’s disease biomarkers. Biomed Environ Sci. 2018;31(2):87–96.
   PubMed Web of Science ®Google Scholar
• Alizadeh M, Safarzadeh A, Beyranvand F, et al. The potential role of miR-29 in health and cancer diagnosis, prognosis, and therapy. J Cell Physiol. 2019;234(11):19280–19297.
   PubMed Web of Science ®Google Scholar
• Guo CM, Liu SQ, Sun MZ. miR-429 as biomarker for diagnosis, treatment and prognosis of cancers and its potential action mechanisms: a systematic literature review. Neoplasma. 2020;67(2):215–228.
   PubMed Web of Science ®Google Scholar
• Liu K, Zhao D, Wang D. LINC00528 regulates myocardial infarction by targeting the miR-143-3p/COX-2 axis. Bioengineered. 2020;11(1):11–18.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhu Q, Lu L, et al. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1. Bioengineered. 2020;11(1):91–102.
   PubMed Web of Science ®Google Scholar
• Ning L, Zhang M, Zhu Q, et al. miR-25-3p inhibition impairs tumorigenesis and invasion in gastric cancer cells in vitro and in vivo. Bioengineered. 2020;11(1):81–90.
   PubMed Web of Science ®Google Scholar
• Tao S, Liu YB, Zhou ZW, et al. miR-3646 promotes cell proliferation, migration, and invasion via regulating G2/M transition in human breast cancer cells. Am J Transl Res. 2016;8(4):1659–1677.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhong S, Xu Y, et al. MicroRNA-3646 contributes to docetaxel resistance in human breast cancer cells by GSK-3β/β-catenin signaling pathway. PloS One. 2016;11(4):e0153194.
   PubMed Web of Science ®Google Scholar
• Qiu H, Zhang Y, Zhao Q, et al. Platelet miR-587 may be used as a potential biomarker for diagnosis of patients with acute coronary syndrome. Clin Lab. 2020;66:3.
   Web of Science ®Google Scholar
• Wu S, Sun H, Sun B. MicroRNA-145 is involved in endothelial cell dysfunction and acts as a promising biomarker of acute coronary syndrome. Eur J Med Res. 2020;25(1):2.
   PubMed Web of Science ®Google Scholar
• Barstow C. Acute coronary syndrome: presentation and diagnostic evaluation. FP Essent. 2020;490:11–19.
   PubMedGoogle Scholar
• Kozinski M, Krintus M, Kubica J, et al. High-sensitivity cardiac troponin assays: from improved analytical performance to enhanced risk stratification. Crit Rev Clin Lab Sci. 2017;54(3):143–172.
   PubMed Web of Science ®Google Scholar
• Pant DC, Mowar AB, Chandra N. Co-relation between total cholesterol, high density lipoprotein, low density lipoprotein and glycosylated haemoglobin (HbA1c) in diabetic patients with acute coronary syndrome (ACS). J Assoc Physicians India. 2018;66(7):20–22.
   PubMedGoogle Scholar
• Zhang JH, Wang CH, Xu J, et al. [Prognostic value of total cholesterol content of erythrocyte membranes in patients with acute coronary syndrome]. Zhonghua Xin Xue Guan Bing Za Zhi. 2019;47(4):305–310.
   PubMedGoogle Scholar
• Al-Zakwani I, Sulaiman K, Al-Rasadi K, et al. Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman. Curr Med Res Opin. 2011;27(4):879–885.
   PubMed Web of Science ®Google Scholar
• Wang X, He Y, Wang T, et al. Lipid-lowering therapy and low-density lipoprotein cholesterol (LDL-C) goal achievement in high-cardiovascular-risk patients in Fuzhou, China. J Cardiovasc Pharmacol Ther. 2020;25(4):307–315.
   PubMed Web of Science ®Google Scholar
• Omidi N, Sadeghian S, Salarifar M, et al. Relationship between the severity of coronary artery disease and cardiovascular risk factors in acute coronary syndrome: based on tehran heart center’s data registry. J Tehran Heart Cent. 2020;15(4):165–170.
   PubMedGoogle Scholar
• Lutgens E, Atzler D, Doring Y, et al. Immunotherapy for cardiovascular disease. Eur Heart J. 2019;40(48):3937–3946.
   PubMed Web of Science ®Google Scholar
• Ren J, Ma R, Zhang ZB, et al. Effects of microRNA-330 on vulnerable atherosclerotic plaques formation and vascular endothelial cell proliferation through the WNT signaling pathway in acute coronary syndrome. J Cell Biochem. 2018;119(6):4514–4527.
   PubMed Web of Science ®Google Scholar